We are pursuing a progranulin gene therapy program because it directly corrects the underlying genetic deficit of FTD-GRN, generates progranulin within the cells rather than delivering it to extracellular compartments, requires a single therapeutic intervention only and is based on an established viral vector technology. Here, GRN is linked to frontotemporal dementia.